PARK7 and amyotrophic lateral sclerosis: In this frame, considering the purported role of DJ-1 in activating the Nrf-2 antioxidative pathway and the possible involvement of this pathway in ALS, the development of effective Nrf-2 activators appears a promising therapeutic strategy to cope with ALS, which deserves consideration [43,44,45,46].